Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study shows that once-daily oral semaglutide significantly improved glycemic control and reduced body weight in adults with type 2 diabetes (T2D) in real-world practice. Treatment satisfaction increased, with a favorable safety profile observed.
Area Of Science
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background
- Real-world assessment of once-daily oral semaglutide in adults with type 2 diabetes (T2D) who have not previously used injectable glucose-lowering medications.
- PIONEER REAL Netherlands study, a phase 4, multicentre, prospective, non-interventional trial.
Purpose Of The Study
- To evaluate the clinical outcomes of oral semaglutide in a real-world setting.
- To assess changes in glycated haemoglobin (HbA1c) and body weight (BW).
- To evaluate treatment satisfaction and safety.
Main Methods
- 187 participants with T2D initiated on oral semaglutide were followed for 34-44 weeks.
- Primary endpoint: change in HbA1c from baseline (BL) to end of study (EOS).
- Secondary endpoints included changes in BW, proportion achieving HbA1c < 7.0%, composite endpoints, and treatment satisfaction via DTSQ.
Main Results
- Significant reductions in HbA1c (-1.16%-points) and BW (-5.84 kg) were observed (p < 0.0001).
- 47.5% achieved HbA1c < 7.0%; 41.8% and 35.5% met composite endpoints for HbA1c and BW reduction.
- Treatment satisfaction scores improved significantly, and 81.5% found oral semaglutide easy to consume.
Conclusions
- Oral semaglutide demonstrated clinically significant efficacy in reducing HbA1c and BW in a real-world T2D population.
- Improved treatment satisfaction and a manageable safety profile, primarily gastrointestinal disorders, were noted.
- The study supports the use of oral semaglutide in routine clinical practice for T2D management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...